adult acute myeloid leukemia with inv(16)(p13;q22)
Information
- Disease name
- adult acute myeloid leukemia with inv(16)(p13;q22)
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02085408 | Active, not recruiting | Phase 3 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | February 4, 2011 | October 2024 |
| NCT01869114 | Active, not recruiting | Phase 2 | Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy | July 8, 2013 | April 19, 2028 |
| NCT01869803 | Approved for marketing | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | |||
| NCT00006363 | Completed | Phase 3 | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | November 2000 | |
| NCT00008177 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | July 27, 1999 | December 15, 2010 |
| NCT00012376 | Completed | Phase 1 | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | March 2001 | |
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00027872 | Completed | Phase 2 | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | October 2001 | January 2009 |
| NCT00039117 | Completed | Phase 1 | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | April 2002 | |
| NCT00040846 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | November 2001 | December 2009 |
| NCT00045396 | Completed | Phase 2 | A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) | June 2002 | |
| NCT00045435 | Completed | Phase 2 | Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission | April 2002 | January 2009 |
| NCT00049504 | Completed | Phase 2 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | January 2002 | February 2014 |
| NCT00052520 | Completed | Phase 1/Phase 2 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | September 2002 | June 2013 |
| NCT00060372 | Completed | Phase 1 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | April 2003 | |
| NCT00062075 | Completed | Phase 2 | Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 2003 | |
| NCT00070551 | Completed | Phase 1 | GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | September 2003 | |
| NCT00077181 | Completed | Phase 1 | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies | January 2004 | |
| NCT00078858 | Completed | Phase 1/Phase 2 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | September 2003 | |
| NCT00079378 | Completed | Phase 1 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | February 2004 | |
| NCT00084916 | Completed | Phase 2 | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase | April 2004 | |
| NCT00085124 | Completed | Phase 3 | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia | December 2003 | |
| NCT00087204 | Completed | Phase 1 | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | May 2004 | |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT00093418 | Completed | Phase 2 | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | September 2004 | |
| NCT00093743 | Completed | Phase 1 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia | January 2000 | |
| NCT00095797 | Completed | Phase 1 | XK469R in Treating Patients With Refractory Hematologic Cancer | October 2004 | |
| NCT00096122 | Completed | Phase 1/Phase 2 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2004 | February 2010 |
| NCT00098423 | Completed | Phase 1 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | November 2004 | |
| NCT00098826 | Completed | Phase 1 | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | December 2004 | |
| NCT02316964 | Completed | Phase 1 | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | April 21, 2015 | December 20, 2019 |
| NCT00005799 | Completed | N/A | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | November 1999 | |
| NCT00005940 | Completed | Phase 2 | Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission | October 1999 | |
| NCT01174888 | Completed | Phase 1 | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | August 2010 | May 2016 |
| NCT01175785 | Completed | Phase 2 | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | August 2010 | August 2014 |
| NCT01177371 | Completed | Phase 2 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | March 1988 | February 2010 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01233921 | Completed | N/A | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | September 2010 | |
| NCT01235572 | Completed | Phase 2 | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | December 2010 | July 2014 |
| NCT01246622 | Completed | Phase 1 | Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | February 7, 2011 | June 5, 2019 |
| NCT01253447 | Completed | Phase 2 | AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | October 2010 | April 2014 |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT01349972 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | April 2011 | May 2014 |
| NCT01384513 | Completed | Phase 2 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | August 4, 2011 | November 16, 2022 |
| NCT01519596 | Completed | N/A | Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | October 2012 | February 5, 2017 |
| NCT01523223 | Completed | Phase 1 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | January 2012 | October 2016 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01555268 | Completed | Phase 1 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | October 31, 2011 | August 3, 2016 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT01707004 | Completed | Phase 2 | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 16, 2013 | October 7, 2017 |
| NCT01768897 | Completed | Phase 1 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | January 2013 | January 2016 |
| NCT01789255 | Completed | Phase 2 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | June 2013 | March 2014 |
| NCT01798901 | Completed | Phase 1 | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | September 17, 2013 | February 19, 2015 |
| NCT01820624 | Completed | Phase 1 | Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | April 30, 2013 | November 13, 2015 |
| NCT01822015 | Completed | Early Phase 1 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | March 15, 2013 | December 12, 2019 |
| NCT01831232 | Completed | N/A | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | May 2013 | January 2016 |
| NCT01839240 | Completed | Phase 1 | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | June 6, 2012 | August 16, 2019 |
| NCT01839916 | Completed | Phase 2 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | April 4, 2013 | August 2018 |
| NCT01842139 | Completed | Phase 1 | Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | December 5, 2011 | March 2018 |
| NCT01869777 | Completed | N/A | Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia | July 2013 | May 2020 |
| NCT01872819 | Completed | N/A | Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay | August 2, 2013 | November 17, 2014 |
| NCT02019069 | Completed | Phase 2 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | February 3, 2014 | December 18, 2017 |
| NCT02122081 | Completed | Phase 1 | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | July 27, 2015 | September 6, 2022 |
| NCT02144675 | Completed | Phase 2 | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | January 2009 | April 26, 2016 |
| NCT02299518 | Completed | Phase 1 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 18, 2015 | March 6, 2018 |
| NCT00003190 | Completed | Phase 3 | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | January 1998 | |
| NCT00101296 | Completed | Phase 1 | Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | October 2004 | |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00112853 | Completed | Phase 1 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | March 2005 | |
| NCT00275080 | Completed | Phase 1 | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | February 2006 | August 2014 |
| NCT00301938 | Completed | Phase 1 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | December 2005 | |
| NCT00305773 | Completed | Phase 2 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | January 2006 | January 2010 |
| NCT00322101 | Completed | Phase 3 | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | January 2006 | October 2014 |
| NCT00331513 | Completed | Phase 1 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | March 2006 | |
| NCT00343798 | Completed | Phase 1 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | April 2006 | |
| NCT00352365 | Completed | Phase 2 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia | June 2006 | July 1, 2011 |
| NCT00357032 | Completed | Phase 2 | PXD101 in Treating Patients With Acute Myeloid Leukemia | May 2006 | July 2010 |
| NCT00357305 | Completed | Phase 1 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | May 2006 | |
| NCT00357708 | Completed | Phase 1 | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | June 2006 | |
| NCT00407966 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2006 | November 2009 |
| NCT00408681 | Completed | N/A | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | June 2006 | May 1, 2015 |
| NCT00445744 | Completed | N/A | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | December 2006 | June 2013 |
| NCT00459212 | Completed | Phase 1 | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | March 2007 | |
| NCT00462605 | Completed | Phase 2 | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | April 2007 | March 2011 |
| NCT00470197 | Completed | Phase 1 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | April 2007 | |
| NCT00475150 | Completed | Phase 2 | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 2008 | March 2012 |
| NCT00489203 | Completed | Phase 2 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | April 2007 | |
| NCT00492401 | Completed | Phase 2 | Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | May 2007 | October 2014 |
| NCT00536601 | Completed | N/A | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | June 29, 2006 | July 9, 2018 |
| NCT00602225 | Completed | Phase 1/Phase 2 | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | December 2007 | April 2015 |
| NCT00602771 | Completed | Phase 2 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | January 2008 | October 2011 |
| NCT00634244 | Completed | Phase 2 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | October 2008 | October 2014 |
| NCT00703300 | Completed | Phase 1 | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia | June 2008 | October 2014 |
| NCT00742625 | Completed | Phase 1/Phase 2 | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | September 2008 | December 2012 |
| NCT00795002 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | November 2008 | September 2012 |
| NCT00795769 | Completed | Phase 2 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | August 8, 2008 | June 10, 2009 |
| NCT00799461 | Completed | Phase 3 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | August 2008 | |
| NCT00839982 | Completed | Phase 1/Phase 2 | Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS | November 2008 | December 2012 |
| NCT00856388 | Completed | N/A | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | January 14, 2009 | March 13, 2019 |
| NCT00860574 | Completed | Phase 2 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | February 2009 | |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT00895934 | Completed | Phase 1/Phase 2 | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | May 2009 | September 2013 |
| NCT01031368 | Completed | Phase 1 | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | December 2009 | October 24, 2012 |
| NCT01056614 | Completed | Phase 2 | Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies | September 2004 | April 2016 |
| NCT01083706 | Completed | Phase 2 | Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | April 2010 | |
| NCT01101880 | Completed | Phase 2 | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm | August 2010 | July 2017 |
| NCT01127009 | Completed | Phase 1 | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | July 2010 | May 2014 |
| NCT01141725 | Completed | Phase 1/Phase 2 | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | September 2010 | November 2012 |
| NCT02094794 | Recruiting | Phase 2 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML | May 12, 2014 | February 28, 2025 |
| NCT01801046 | Terminated | Phase 1 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | March 6, 2013 | August 20, 2017 |
| NCT00103272 | Terminated | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | April 2005 | |
| NCT01904643 | Terminated | Phase 1 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | February 2014 | July 18, 2015 |
| NCT02105116 | Terminated | N/A | AML Therapy With Irradiated Allogeneic Cells | February 2014 | December 16, 2015 |
| NCT00119366 | Terminated | Phase 2 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 2003 | May 8, 2019 |
| NCT01342887 | Terminated | Phase 1/Phase 2 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | April 2011 | March 2012 |
| NCT00301769 | Terminated | Phase 1 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | December 2005 | |
| NCT02029417 | Terminated | Phase 2 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | July 2014 | December 2015 |
| NCT02030405 | Terminated | Phase 2 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | March 2014 | November 2015 |
| NCT01521936 | Terminated | Phase 2 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy | December 2011 | June 2015 |
| NCT00863434 | Terminated | Phase 2 | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease | February 2009 | |
| NCT02049801 | Terminated | Phase 1 | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | December 2014 | November 1, 2017 |
| NCT00673153 | Terminated | Phase 2 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | March 2008 | |
| NCT00039091 | Terminated | Phase 1 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | March 2002 | November 21, 2007 |
| NCT00540995 | Terminated | Phase 1/Phase 2 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer | June 11, 2007 | August 9, 2011 |
| NCT00049582 | Terminated | Phase 1 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2002 | |
| NCT01876953 | Terminated | Phase 1/Phase 2 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | September 13, 2013 | April 25, 2018 |
| NCT00101231 | Terminated | Phase 1 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | October 2004 | |
| NCT01550185 | Terminated | Phase 1 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | May 2012 | December 2014 |
| NCT00387426 | Terminated | Phase 2 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | September 2006 | February 2009 |
| NCT01076270 | Terminated | N/A | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | June 2010 | February 2011 |
| NCT01849276 | Terminated | Phase 1 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | March 11, 2015 | January 21, 2016 |
| NCT01564277 | Terminated | Phase 2 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | September 29, 2011 | May 28, 2016 |
| NCT00052598 | Terminated | Phase 1/Phase 2 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | September 2002 | June 2011 |
| NCT01159067 | Terminated | Phase 2 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | July 2010 | August 9, 2011 |
| NCT01159301 | Terminated | Phase 1 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | June 2010 | |
| NCT01607645 | Terminated | Phase 2 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | July 2012 | September 2013 |
| NCT02071901 | Unknown status | Phase 2 | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | August 14, 2014 | September 26, 2023 |
| NCT01548911 | Withdrawn | Phase 2 | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | May 2012 | September 2013 |
| NCT01652014 | Withdrawn | Phase 2 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | January 2014 | January 2017 |
| NCT01558778 | Withdrawn | N/A | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | May 2012 | |
| NCT01835288 | Withdrawn | Phase 2 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 2013 |